Carlo Pifferi

Carlo Pifferi

Auto-generated profile, based on publicly available information

Carlo Pifferi

Chemical Immunology Laboratory Center for Cooperative Research in Biosciences (CIC bioGUNE) Basque Research and Technology Alliance (BRTA) Derio Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in Nature Reviews Chemistry
Verified
Journal Article
Open access
PDF file
CPCarlo Pifferi
Carlo Pifferi
RFRoberto Fuentes
Roberto Fuentes
AFAlberto Fernández-Tejada
Alberto Fernández-Tejada
Modern subunit vaccines based on homogeneous antigens offer more precise targeting and improved safety compared with traditional whole-pathogen vaccines. However, they are also less immunogenic and require an adjuvant to increase the immunogenicity of the antigen and potentiate the immune response. Unfortunately, few adjuvants have sufficient potency and low enough toxicity for clinical use, highlighting the urgent need for new, potent and safe adjuvants. Notably, a number of natural and synthetic carbohydrate structures have been used as adjuvants in clinical trials, and two have recently been approved in human vaccines. However, naturally derived carbohydrate adjuvants are heterogeneous, difficult to obtain and, in some cases, unstable. In addition, their molecular mechanisms of action are generally not fully understood, partly owing to the lack of tools to elucidate their immune-potentiating effects, thus hampering the rational development of optimized adjuvants. To address these challenges, modification of the natural product structure using synthetic chemistry emerges as an attractive approach to develop well-defined, improved carbohydrate-containing adjuvants and chemical probes for mechanistic investigation. This Review describes selected examples of natural and synthetic carbohydrate-based adjuvants and their application in synthetic self-adjuvanting vaccines, while also discussing current understanding of their molecular mechanisms of action.

12 July 2016 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
JRJoão P Ribeiro
João P Ribeiro
WPWilliam K. Pau
William K. Pau
CPCarlo Pifferi
Carlo Pifferi
OROlivier Renaudet
Olivier Renaudet
AVAnnabelle Varrot
Annabelle Varrot
AIAnne Imberty
Anne Imberty
Carbohydrate-binding modules (CBMs) are a class of polypeptides usually associated with carbohydrate-active enzymatic sites. We have characterized a new member of the family CBM40, coded from a section of the gene NanI from Clostridium perfringens. Glycan arrays revealed its preference towards α(2,3)-linked sialosides, that was confirmed and quantified by calorimetric studies. The CBM40 binds to α(2,3)-sialyllactose with a Kd ~ 30 μM, a leading affinity value for this class of proteins. Inspired on nature work and its creation of multimeric proteins, we have engineered a dimeric form of the CBM, and using SPR we have observed 6-11 fold binding increases due to the avidity affect. The structures of the CBM, resolved by X-ray crystallography, in complex with α(2,3)- or α(2,6)-sialyllactose explain its binding specificity and unusually strong binding.

11 June 2020 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
VPVanessa Porkolab
Vanessa Porkolab
CPCarlo Pifferi
Carlo Pifferi
ISIeva Sutkeviciute
Ieva Sutkeviciute
SOStefania Ordanini
Stefania Ordanini
MTMarwa Taouai
Marwa Taouai
FFFranck Fieschi
Franck Fieschi
Multivalent interactions between complex carbohydrates and oligomeric C-type lectins govern a wide range of immune responses. Up to date, standard SPR (surface plasmon resonance) competitive assays have largely been to evaluate binding properties from monosaccharide units (low affinity, mM) to multivalent elemental antagonists (moderate affinity, μM). Herein, we report typical case-studies of SPR competitive assays showing that they underestimate the potency of glycoclusters to inhibit the interaction between DC-SIGN and immobilized glycoconjugates. This paper describes the design and implementation of a SPR direct interaction over DC-SIGN oriented surfaces, extendable to other C-type lectin surfaces as such Langerin. This setup provides an overview of intrinsic avidity generation emanating simultaneously from multivalent glycoclusters and from DC-SIGN tetramers organized in nanoclusters at the cell membrane. To do so, covalent biospecific capture of DC-SIGN via StreptagII/StrepTactin interaction preserves tetrameric DC-SIGN, accessibility and topology of its active sites, that would have been dissociated using standard EDC–NHS procedure under acidic conditions. From the tested glycoclusters libraries, we demonstrated that the scaffold architecture, the valency and the glycomimetic-based ligand are crucial to reach nanomolar affinities for DC-SIGN. The glycocluster 3·D illustrates the tightest binding partner in this set for a DC-SIGN surface (KD = 18 nM). Moreover, the selectivity at monovalent scale of glycomimetic D can be easily analyzed at multivalent scale comparing its binding over different C-type lectin immobilized surfaces. This approach may give rise to novel insights into the multivalent binding mechanisms responsible for avidity and make a major contribution to the full characterization of the binding potency of promising specific and multivalent immodulators.

6 July 2017 in Chemical Reviews
Verified
Journal Article
Closed access
CPCarlo Pifferi
Carlo Pifferi
GDGour Chand Daskhan
Gour Chand Daskhan
Michele FioreMichele Fiore
Michele Fiore
TSTze Chieh Shiao
Tze Chieh Shiao
René RoyRené Roy
René Roy
OROlivier Renaudet
Olivier Renaudet

25 October 2017 in Chemistry – A European Journal
Verified
Journal Article
Open access
PDF file
CPCarlo Pifferi
Carlo Pifferi
BTBaptiste Thomas
Baptiste Thomas
DGDavid Goyard
David Goyard
NBNathalie BERTHET
Nathalie BERTHET
OROlivier Renaudet
Olivier Renaudet
The large majority of TACA‐based (TACA=Tumor‐Associated Carbohydrate Antigens) antitumor vaccines target only one carbohydrate antigen, thereby often resulting in the incomplete destruction of cancer cells. However, the morphological heterogeneity of the tumor glycocalix, which is in constant evolution during malignant transformation, is a crucial point to consider in the design of vaccine candidates. In this paper, an efficient synthetic strategy based on orthogonal chemoselective ligations to prepare fully synthetic glycosylated cyclopeptide scaffolds grafted with both Tn and TF antigen analogues is reported. To evaluate their ability to be recognized as tumor antigens, direct interaction ELISA assays have been performed with the anti‐Tn monoclonal antibody 9A7. Although both heterovalent structures showed binding capacities with 9A7, the presence of the second TF epitope did not interfere with the recognition of Tn except in one epitope arrangement. This heterovalent glycosylated structure thus represents an attractive epitope carrier to be further functionalized with T‐cell peptide epitopes.

9 March 2017 in Biomaterials Science
Verified
Journal Article
Open access
PDF file
CPCarlo Pifferi
Carlo Pifferi
NBNathalie BERTHET
Nathalie BERTHET
OROlivier Renaudet
Olivier Renaudet
Cyclopeptides have been recently used successfully as carriers for the multivalent presentation of carbohydrate and peptide antigens in immunotherapy.